In vivo correction of a Menkes disease model using antisense oligonucleotides.
about
Menkes disease: what a multidisciplinary approach can doMottled Mice and Non-Mammalian Models of Menkes DiseaseA short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophyATP7A-related copper transport diseases-emerging concepts and future trendsZebrafish mutants calamity and catastrophe define critical pathways of gene-nutrient interactions in developmental copper metabolismIdentification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular AtrophyRole of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis.Therapeutic potential of splice-switching oligonucleotides.A gain of function mutation causing skeletal overgrowth in the rapunzel mutant.Zebrafish in the sea of mineral (iron, zinc, and copper) metabolism.Occipital horn syndrome and classical Menkes Syndrome caused by deep intronic mutations, leading to the activation of ATP7A pseudo-exon.New insights in gene-derived therapy: the example of Duchenne muscular dystrophy.An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome.Zebrafish as a model for systems biology.Modelling inborn errors of metabolism in zebrafish.Nkcc1 (Slc12a2) is required for the regulation of endolymph volume in the otic vesicle and swim bladder volume in the zebrafish larva.Pseudoexon exclusion by antisense therapy in 6-pyruvoyl-tetrahydropterin synthase deficiency.Aspergillus fumigatus Copper Export Machinery and Reactive Oxygen Intermediate Defense Counter Host Copper-Mediated Oxidative Antimicrobial Offense.Mutation of IPO13 causes recessive ocular coloboma, microphthalmia, and cataract.Zebrafish Models of Rare Hereditary Pediatric Diseases.Copper metabolism and inherited copper transport disorders: molecular mechanisms, screening, and treatment
P2860
Q26738363-C8707D5C-CC4D-4644-8E46-0B6323E9776FQ26770905-B0694988-0A83-4AFC-84DC-53E74E7BF470Q28244480-F0F76716-A66A-41D5-A5D9-4F861C23A5EDQ28302938-E7A9BD5B-2DE6-4394-B11A-8B25A3488791Q28473993-29DB2465-F0F8-41E6-88D5-29970E092783Q33786251-69DD07BA-E51C-4D56-A7CF-C91C8D9624B4Q37112824-AA3055B2-41E8-44F5-BE57-7B5D22CC3D1DQ37363171-8CC59237-E529-4BF9-8671-FA439F9ECE2BQ37374581-076A37FD-CCC7-4C16-887C-59386E74FE07Q37621602-CC98648C-A90F-49C2-A651-752B3B306C06Q37636761-73B0B24D-975A-4CEF-9A92-76D6FB306DA1Q37814437-0B40B2D1-00A8-4AE7-8498-34CF54DC9A03Q38071046-BFFCEA63-946C-4065-987D-A7B6B73ADDB0Q38191016-BABD46A2-A88F-42B6-9302-14BA19187FD5Q38209473-6CF31AE5-B47A-4930-A693-30A915274C52Q41876790-5D95ACDF-3243-4902-B56A-579043226845Q46849509-CD07A439-0A17-416D-9124-06D663F640B0Q51152833-04B64AD9-A6E5-4ACC-A72D-14545B69B068Q52560217-0A4D6899-AFB8-4012-B58A-72E12C9A52CFQ55429803-ECFCFFD8-828A-47B9-AAEF-F3D257656254Q56552176-E24569BB-E7A8-4CF8-9C00-2B8C3B583372
P2860
In vivo correction of a Menkes disease model using antisense oligonucleotides.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@ast
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@en
type
label
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@ast
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@en
prefLabel
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@ast
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@en
P2093
P2860
P356
P1476
In vivo correction of a Menkes disease model using antisense oligonucleotides.
@en
P2093
Bryce A Mendelsohn
Erik C Madsen
Jonathan D Gitlin
Paul A Morcos
P2860
P304
P356
10.1073/PNAS.0710865105
P407
P577
2008-03-03T00:00:00Z